Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 9/20 | 0.58 |
| ▸ | ELOC | Q15369 | 2/20 | 0.58 |
| ▸ | ELOB | Q15370 | 2/20 | 0.58 |
| ▸ | NAMPT | P43490 | 5/20 | 0.52 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.51 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18530428 | 0.86 | VHL (0.60) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL25414216 | 0.86 | VHL (0.60) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL18530426 | 0.86 | VHL (0.60) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL29817228 | 0.85 | VHL (0.66) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL31228127 | 0.83 | VHL (0.73) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL24611063 | 0.83 | VHL (0.72) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL22186168 | 0.83 | VHL (0.75) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL22325243 | 0.83 | VHL (0.75) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL22325241 | 0.83 | VHL (0.75) | VHLELOCELOBNAMPTEGFR | |
| SCHEMBL25310312 | 0.83 | VHL (0.67) | VHLELOCELOBNAMPTEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | ARVINAS OPERATIONS, INC. | 2023-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230263893-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS | BRPF3, STUB1, BRDT | VHL 11/4885ELOC 251/4885ELOB 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.